10 8 Tumor burden reduction by a combination of BV and DHAP treatment is attractive because DHAP by itself is well tolerated in patients with R/R cHL and results in 20% complete remission (CR) and 70% partial remission and 50-60% metabolic CR (CMR) while stem cell mobilization potential is maintained. However, the combination of BV with multi-agent chemotherapy can be associated with significant toxicity. 5 4īrentuximab vedotin has already been combined with standard therapy in a sequential strategy and concurrently with chemotherapy regimens such as ESHAP (etoposide, methylprednisolone, cytarabine and cisplatin) before HDC-ASCT, 11 6 and resulted in a CMR rate of more than 75% prior to HDC-ASCT. 3 Combining BV and chemotherapy prior to high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) might lower the tumor burden and decrease the relapse rate after HDC-ASCT and thus contribute to cure. 2 1 Adverse events ascribed to BV as single agent are mostly mild and reversible. Clinical activity of brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, has been demonstrated in relapsed/refractory classical Hodgkin Lymphoma (R/R cHL) in pivotal phase I and phase II studies.
0 kommentar(er)
